<DOC>
	<DOC>NCT00862394</DOC>
	<brief_summary>To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding dose of CHF 1535 via HFA-134a "extrafine" pMDI in terms of pulmonary function in moderate to severe symptomatic asthmatic patients aged ≥ 12 years under treatment with inhaled corticosteroids</brief_summary>
	<brief_title>A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Written informed consent Outpatients of both sexes, aged &gt; 12 years Moderate to severe symptomatic asthma Forced expiratory volume in the first second (FEV1) &gt; 40% and &lt; 80% of the predicted normal values Reversibility test "Partly controlled" asthma (GINA revised 2006) Patients free of longacting beta2agonists (LABAs) treatment Under inhaled corticosteroids (ICS) treatment A minimum inspiratory flow ≥ 40 L/min 10. Nonsmokers or ex smokers Asthma Control Questionnaire ACQ score ≥ 1.5 Pregnant or nursing (lactating) women Women of childbearing potential, UNLESS they are menopausal or have acceptable methods of contraception Significant seasonal variation in asthma or asthma occurring only during episodic exposure to an allergen or a chemical sensitizer History of near fatal asthma Occurrence of asthma exacerbations or respiratory tract infections in the 6 weeks preceding the screening visit Diagnosis COPD History of cystic fibrosis, bronchiectasis or alpha1 antitrypsin deficiency Diagnosis of restrictive lung disease Patients treated with oral or parenteral corticosteroids in the previous 2 months (3 months for parenteral depot corticosteroids) Intolerance or contraindication to treatment with beta2agonists and/or inhaled corticosteroids Allergy to any component of the study treatments Any change in the dose, schedule, formulation or product of an inhaled corticosteroid in the 4 weeks prior to screening visit Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality ; Patients with abnormal QTc</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>